Lonza, a CDMO, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company developing genetic therapies for severe rare diseases, have extended their long-term commercial manufacturing agreement.  Lonza will expand manufacturing capacity to support growing demand for Genetix’s ZYNTEGLO, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia.

 The agreement extends the strategic collaboration established in 2...